Effects of fasudil on pulmonary hypertension in clinical practice.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pulmonary Pharmacology & Therapeutics

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pupt.2017.08.002PMID 28782712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity

  2017cited by this paper
• Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.

  2016cited by this paper
• Endothelin-1-Rho kinase interactions impair lung structure and cause pulmonary hypertension after bleomycin exposure in neonatal rat pups.

  2016cited by this paper
• Pulmonary vascular remodeling in pulmonary hypertension

  2016cited by this paper
• RhoA/Rho-Kinase in the Cardiovascular System.

  2016cited by this paper
• Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials

  2016cited by this paper
• Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs.

  2016cited by this paper
• Time Dependence of the Effect of Right Ventricular Dysfunction on Clinical Outcomes After Myocardial Infarction: Role of Pulmonary Hypertension

  2016cited by this paper
• Blunted Activation of Rho-Kinase in Yak Pulmonary Circulation

  2015cited by this paper
• Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension

  2015cited by this paper
• New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.

  2015cited by this paper
• Rho Kinases in Health and Disease: From Basic Science to Translational Research

  2015cited by this paper
• 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

  2015cited by this paper
• Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.

  2015cited by this paper
• Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension

  2015cited by this paper
• Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.

  2015cited by this paper
• Management of pulmonary arterial hypertension.

  2015cited by this paper
• TWIK-2 Channel Deficiency Leads to Pulmonary Hypertension Through a Rho-Kinase–Mediated Process

  2014cited by this paper
• Concurrent Rho-Kinase and Tyrosine Kinase Platelet-Derived Growth Factor Inhibition in Experimental Pulmonary Hypertension

  2014cited by this paper
• Atorvastatin attenuates involvement of RhoA/Rho‐kinase pathway and NF‐&kgr;B activation in hypoxic pulmonary hypertensive rats

  2014cited by this paper
• Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.

  2014cited by this paper
• Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature.

  2014cited by this paper
• Ripasudil: First Global Approval

  2014cited by this paper
• Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.

  2014cited by this paper
• Rho-associated coiled-coil containing kinases (ROCK)

  2014cited by this paper
• Long-Term Data from the Swiss Pulmonary Hypertension Registry

  2014cited by this paper
• Peptide-Coated Liposomal Fasudil Enhances Site Specific Vasodilation in Pulmonary Arterial Hypertension

  2014cited by this paper
• Molecular Mechanisms of Pulmonary Arterial Remodeling

  2014cited by this paper
• Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry

  2014cited by this paper
• Pulmonary hypertension in cystic fibrosis with advanced lung disease.

  2014cited by this paper
• Crucial Role of ROCK2 in Vascular Smooth Muscle Cells for Hypoxia-Induced Pulmonary Hypertension in Mice

  2013cited by this paper
• Pulmonary arterial hypertension: epidemiology and registries.

  2013cited by this paper
• Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.

  2013cited by this paper
• Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

  2013cited by this paper
• Relevant issues in the pathology and pathobiology of pulmonary hypertension.

  2013cited by this paper
• Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

  2013cited by this paper
• Rho Kinases in Cardiovascular Physiology and Pathophysiology: The Effect of Fasudil

  2013cited by this paper
• Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep

  2013cited by this paper
• Hemodynamic predictors of mortality in adults with sickle cell disease.

  2013cited by this paper
• Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.

  2013cited by this paper
• Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.

  2013cited by this paper
• The Beneficial Impact of Fasudil and Sildenafil on Monocrotaline-Induced Pulmonary Hypertension in Rats: A Hemodynamic and Biochemical Study

  2013cited by this paper
• Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease.

  2012cited by this paper
• Atorvastatin in Pulmonary Arterial Hypertension (APATH) study

  2012cited by this paper
• Effects of fasudil in patients with high-altitude pulmonary hypertension

  2012cited by this paper
• Targeting RhoA/ROCK pathway in pulmonary arterial hypertension

  2012cited by this paper
• Endothelin-1 Augments Na+/H+ Exchange Activity in Murine Pulmonary Arterial Smooth Muscle Cells via Rho Kinase

  2012cited by this paper
• Key role of the RhoA/Rho kinase system in pulmonary hypertension.

  2011cited by this paper
• Rho-kinase: important new therapeutic target in cardiovascular diseases.

  2011cited by this paper
• Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery Hypertension

  2011cited by this paper
• Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

  2011cited by this paper
• Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT

  2011cited by this paper
• Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

  2010cited by this paper
• Simvastatin as a treatment for pulmonary hypertension trial.

  2010cited by this paper
• Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil

  2010cited by this paper
• Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension

  2010cited by this paper
• Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension

  2010cited by this paper
• Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry.

  2010cited by this paper
• Analysis of Pulmonary Vasodilator Responses to SB-772077-B [4-(7-((3-Amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a Novel Aminofurazan-Based Rho Kinase Inhibitor

  2009cited by this paper
• RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling.

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension.

  2009cited by this paper
• Development and pathology of pulmonary hypertension.

  2009cited by this paper
• Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension.

  2009cited by this paper
• Acute Inhibition of Rho-Kinase Attenuates Pulmonary Hypertension in Patients with Congenital Heart Disease

  2009cited by this paper
• Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide.

  2008cited by this paper
• PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.

  2008cited by this paper
• A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

  2008cited by this paper
• Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats

  2007cited by this paper
• A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage.

  2007cited by this paper
• Systemic Availability of the Active Metabolite Hydroxy‐Fasudil After Administration of Fasudil to Different Sites of the Human Gastrointestinal Tract

  2007cited by this paper
• Effects of Combined Therapy With a Rho-Kinase Inhibitor and Prostacyclin on Monocrotaline-Induced Pulmonary Hypertension in Rats

  2007cited by this paper
• Endothelin-1 and Serotonin are Involved in Activation of RhoA/Rho Kinase Signaling in the Chronically Hypoxic Hypertensive Rat Pulmonary Circulation

  2007cited by this paper
• Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.

  2007cited by this paper
• Acute Vasodilator Effect of Fasudil, a Rho-kinase Inhibitor, in Monocrotaline-Induced Pulmonary Hypertension in Rats

  2007cited by this paper
• Pathology of pulmonary hypertension.

  2007cited by this paper
• A USA-based registry for pulmonary arterial hypertension: 1982–2006

  2007cited by this paper
• Efficacy of a direct puncture approach for anterior circulation aneurysms using a newly developed guiding catheter - especially for geriatric patients.

  2007cited by this paper
• Long-Term Inhibition of Rho-kinase Ameliorates Hypoxia-Induced Pulmonary Hypertension in Mice

  2006cited by this paper
• The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

  2006cited by this paper
• Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.

  2006cited by this paper
• Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension

  2005cited by this paper
• Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage.

  2005cited by this paper
• Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.

  2005cited by this paper
• Prostacyclin Does Not Inhibit Rho-Kinase: An Implication for the Treatment of Pulmonary Hypertension

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.

  2005cited by this paper
• Inhibition of Rho-Kinase Attenuates Hypoxia-Induced Angiogenesis in the Pulmonary Circulation

  2005cited by this paper
• Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

  2005cited by this paper
• Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial.

  2005cited by this paper
• Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats

  2004cited by this paper
• Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats.

  2004cited by this paper
• Monitoring the Cellular Effects of HMG-CoA Reductase Inhibitors In Vitro and Ex Vivo

  2004cited by this paper
• Sildenafil Prevents Change in RhoA Expression Induced by Chronic Hypoxia in Rat Pulmonary Artery

  2003cited by this paper
• Anti-anginal Effect of Fasudil, a Rho-Kinase Inhibitor, in Patients With Stable Effort Angina: A Multicenter Study

  2002cited by this paper
• Impact of HMG CoA reductase inhibition on small GTPases in the heart.

  2002cited by this paper
• Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.

  2001cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors

  2000cited by this paper
• Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase.

  1999cited by this paper

• Integrating RhoA/Rho-Kinase inhibitors with herbal medicine: a novel approach for pulmonary arterial hypertension therapy

  2026cites this paper
• Role of RhoA-ROCK signaling inhibitor fasudil in Alzheimer disease.

  2025cites this paper
• Four Novel Rho‐associated Coiled‐coil Protein Kinase 1 Inhibitors Suppressing Cytoskeleton and Movement in Breast Cancer Cells

  2025cites this paper
• Roles of small GTPases in cardiac hypertrophy (Review)

  2024cites this paper
• Effect of fasudil on clinical outcomes of pulmonary hypertension: a systematic review and meta-analysis

  2024cites this paper
• Cytoskeletal and inter-cellular junction remodelling in endometrial organoids under oxygen-glucose deprivation: a new potential pathological mechanism for thin endometria.

  2024cites this paper
• New and emerging therapies for systemic lupus erythematosus.

  2024cites this paper
• Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats

  2024cites this paper
• Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery.

  2024cites this paper
• Anti-astmatic effect of ROCK inhibitor, GSK429286 A, in experimentally induced allergic airway inflammation

  2024cites this paper
• Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway.

  2024cites this paper
• Analysis of differentially expressed genes in hypertension and hypertensive cerebral hemorrhage via RNA-sequencing

  2024cites this paper
• New Drugs and Therapies in Pulmonary Arterial Hypertension

  2023cites this paper
• Initial real-world experience of clazosentan for subarachnoid hemorrhage in Japan

  2023cites this paper
• Novel cardiovascular protective effects of RhoA signaling and its therapeutic implications.

  2023cites this paper
• Fasudil inhibits the expression of C/EBP homologous protein to protect against liver injury in acetaminophen-overdosed mice.

  2023cites this paper
• Investigation of the ubiquitin proteasome system in pulmonary arterial hypertension

  2023cites this paper
• Tankyrase inhibition interferes with junction remodeling, induces leakiness, and disturbs YAP1/TAZ signaling in the endothelium

  2023cites this paper
• Effects of Butylphthalide Combined with Fasudil on Inflammatory Factors, Cognitive Function and Vascular Endothelial Function in Patients with Subarachnoid Hemorrhage Complicated with Cerebral Vasospasm

  2023cites this paper
• Natural Targeting Potent ROS‐Eliminating Tungsten‐Based Polyoxometalate Nanodots for Efficient Treatment of Pulmonary Hypertension

  2023cites this paper
• Modulating T Cell Phenotype and Function to Treat Hypertension

  2023cites this paper
• DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.

  2022cites this paper
• The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis

  2022cites this paper
• Pharmaceutical Therapies for Chronic Obstructive Pulmonary Disease Complicated by Pulmonary Hypertension

  2022cites this paper
• Key role of Rho GTPases in motor disorders associated with neurodevelopmental pathologies

  2022cites this paper
• Therapeutic Validation of GEF-H1 Using a De Novo Designed Inhibitor in Models of Retinal Disease

  2022cites this paper
• RhoA/ROCK2 signalling is enhanced by PDGF‐AA in fibro‐adipogenic progenitor cells: implications for Duchenne muscular dystrophy

  2022cites this paper
• Effect of nimodipine combined with fasudil on vascular endothelial function and inflammatory factors in patients with cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.

  2022cites this paper
• Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis

  2022cites this paper
• protects against pulmonary artery hypertension induced by monocrotaline via the TGF‑ β 1/p38 MAPK/CREB signaling pathway

  2021cites this paper
• Mechanism of α1-Adrenergic Receptor-Induced Increased Contraction of Rat Mesenteric Artery in Aging Hypertension Rats

  2021cites this paper
• Cyanidin-3-O-β-glucoside protects against pulmonary artery hypertension induced by monocrotaline via the TGF-β1/p38 MAPK/CREB signaling pathway

  2021cites this paper
• Articular Chondrocyte Phenotype Regulation through the Cytoskeleton and the Signaling Processes That Originate from or Converge on the Cytoskeleton: Towards a Novel Understanding of the Intersection between Actin Dynamics and Chondrogenic Function

  2021cites this paper
• RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells in DMD

  2021cites this paper
• New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine

  2021cites this paper
• Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.

  2021cites this paper
• Mechanosensing and Mechanotransduction in Pulmonary Hypertension

  2021cites this paper
• ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension

  2021cites this paper
• LncRNA PAXIP1‐AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis

  2021cites this paper
• Characterization of Contractile Machinery of Vascular Smooth Muscles in Hypertension

  2021influential citation
• Targeting ROCK2 isoform with its widely used inhibitors for faster post-stroke recovery

  2021cites this paper
• A Rho kinase inhibitor (Fasudil) suppresses TGF-β mediated autophagy in urethra fibroblasts to attenuate traumatic urethral stricture (TUS) through re-activating Akt/mTOR pathway: An in vitro study.

  2020cites this paper
• Fasudil attenuates glial cell-mediated neuroinflammation via ERK1/2 and AKT signaling pathways after optic nerve crush

  2020cites this paper
• Involvement of G proteins and Rho kinase in α1-Adrenoceptor mediated contractions of rat portal vein.

  2020cites this paper
• Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments.

  2020cites this paper
• Prolonged treatment with Y-27632 promotes the senescence of primary human dermal fibroblasts by increasing the expression of IGFBP-5 and transforming them into a CAF-like phenotype

  2020cites this paper
• Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application

  2020cites this paper
• Kv7 Channels in Lung Diseases

  2020cites this paper
• RhoA/ROCK pathway inhibitor ameliorates erectile dysfunction induced by radiation therapy in rats.

  2020cites this paper
• The Local and Peripheral Immune Responses to Stroke: Implications for Therapeutic Development

  2020cites this paper
• Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury

  2020cites this paper
• Membrane depolarization is required for pressure-dependent pulmonary arterial tone but not enhanced vasoconstriction to endothelin-1 following chronic hypoxia

  2020cites this paper
• Reduction of Brain Injury After Stroke in Hyperglycemic Rats via Fasudil Pretreatment

  2019cites this paper
• Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis

  2019cites this paper
• The Search for Disease-Modifying Therapies in Pulmonary Hypertension

  2019cites this paper
• Abnormal pulmonary artery systolic pressure response after exercise in systemic sclerosis patients

  2019cites this paper
• Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases

  2019cites this paper
• Reduction of Brain Injury After Stroke in Hyperglycemic Rats via Fasudil Pretreatment

  2019cites this paper
• Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction

  2019cites this paper
• Pre-treatment With Fasudil Prevents Neomycin-Induced Hair Cell Damage by Reducing the Accumulation of Reactive Oxygen Species

  2019cites this paper
• Inhibition of Rho-Kinase Downregulates Th17 Cells and Ameliorates Hepatic Fibrosis by Schistosoma japonicum Infection

  2019cites this paper
• The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.

  2019cites this paper
• P2X7 receptor is involved in lung injuries induced by ischemia‐reperfusion in pulmonary arterial hypertension rats

  2018cites this paper
• Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end-stage pulmonary hypertension with left heart disease

  2018cites this paper
• Inhalation of repurposed drugs to treat pulmonary hypertension☆

  2018cites this paper
• Vascular smooth muscle contraction in hypertension

  2018cites this paper
• Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.

  2018cites this paper
• Mechanobiological Feedback in Pulmonary Vascular Disease

  2018cites this paper